Alejandro Ruiz, Spain

Medicsensors Ltd. Business Development
As a pharmacist and a passionate for technology, working for Medicsen to improve our chances to launch the first non-invasive Artificial Pancreas became a perfect fit to fulfil my professional interests. We develop the first non-invasive transdermal and wearable insulin injector as the first step to an Artificial Pancreas, a device that will reach the market in 2023. This devices uses sonophoresis to painlessly inject macromolecules like insulin, through the patient´s skin. The application of ultrasounds to the skin creates a temporary disruption of the upper skin layer, allowing us to administrate insulin to the intra-dermal and subcutaneous tissue with no need of needles. The ultimate goal of this wearable and painless device is to increase the adherence to the treatment, remove social and physiological burdens and increase millions of chronic patients´quality of life. Get in contact to know more about us and our technology.

Presenter of 1 Presentation

 Conference Calendar
ORAL PRESENTATION SESSION

TRANSDERMAL INSULIN TRANSPORT BY SONOPHORESIS, AN APPROACH TO THE ARTIFICIAL PANCREAS.

Date
Fri, 04.06.2021
Session Name
350 - Oral Presentation 10 (ID 72)
Lecture Time
17:55 - 18:05
Presenter
Authors

Abstract

Background and Aims

Insulin, the main hormone for modulating blood glucose levels, is used for diabetes treatment mainly through subcutaneous injections. This can lead to poor patient compliance and side-effects. To face this problem, Medicsen is developing a Smartpatch with a wide range of tested technologies, focused on the non-invasive, controlled and painless insulin transdermal delivery through sonophoresis.

Methods

In vitro and in vivo tests, such as the permeability phenomenon using Franz diffusion Cell and swine model, or biochemical, chromatography or circular dichroism tests, among others, have been performed to prove the efficacy and safety of the technology.

Results

Lack of damage was observed on insulin molecule, which maintain its biological function and stability, as seen in vivo, in HPLC studies and in the circular dichroism spectra of the samples (Fig. 1), which shows no variability, reaching the characteristic minimum at 219nm (sd+/-8.31) in all groups tested. TEM images of skin, ELISA of skin damage markers TNF a and IL-2 (Fig. 2), and other biochemical tests, show no significant changes in the tissue or in the expression and concentration of relevant compounds. Lastly, the technology proved to be effective in the non-invasive insulin delivery through the skin, as observed in our system and in the in vivo model of blood glucose reduction.

1 800x600.jpg

2 800x600.jpg

Conclusions

All evidence collected during in vitro and in vivo studies show promising results, indicating that the technology developed by Medicsen is safe and effective. Thus, human trials will be performed in order to demonstrate its potential on diabetes treatment.

Hide